Ferdinand Roda, MD
Family Medicine · Hot Springs, ARNPI 1124127634
Payments from drug & device makers
Across 247 payments — averaging $16.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$576
- Acadia Pharmaceuticals Inc$488
- Teva Pharmaceuticals USA, Inc.$427
- Neurocrine Biosciences, Inc.$384
- Lundbeck LLC$354
- Sumitomo Pharma America, Inc.$314
- plus $2K from 21 others
What the payments were for
- Food & beverage$3,94995%
- Education$2245%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 34 | $576 |
| Acadia Pharmaceuticals Inc | 35 | $488 |
| Teva Pharmaceuticals USA, Inc. | 16 | $427 |
| Neurocrine Biosciences, Inc. | 20 | $384 |
| Lundbeck LLC | 20 | $354 |
| Sumitomo Pharma America, Inc. | 22 | $314 |
| Avanir Pharmaceuticals, Inc. | 16 | $231 |
| E.r. Squibb & Sons, L.L.C. | 8 | $230 |
| Vanda Pharmaceuticals Inc. | 20 | $212 |
| Urovant Sciences Inc | 7 | $173 |
| Lilly USA, LLC | 11 | $171 |
| Biogen | 6 | $103 |
| Novartis | 6 | $94 |
| Sunovion Pharmaceuticals Inc. | 5 | $63 |
| Johnson & Johnson | 3 | $55 |
| Astellas Pharma US Inc | 3 | $54 |
| Sun Pharmaceutical Industries Inc. | 3 | $42 |
| Boston Scientific | 2 | $38 |
| Paratek Pharmaceuticals, Inc. | 2 | $38 |
| Aimmune Therapeutics, Inc. | 1 | $24 |
| GSK | 1 | $17 |
| Pfizer | 1 | $15 |
| AbbVie | 1 | $15 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Ferring Pharmaceuticals Inc. | 1 | $13 |
| CMP Pharma, Inc. | 1 | $12 |
How this compares
$4,174 in reported general payments places this provider in the 80th percentile of 1,347 family medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 63 | $247,809 |
| EliquisApixaban | 495 | $151,641 |
| GemtesaVibegron | 549 | $145,434 |
| RexultiBrexpiprazole | 103 | $84,647 |
| EntrestoSacubitril/Valsartan | 200 | $66,396 |
| JardianceEmpagliflozin | 171 | $66,134 |
| LinzessLinaclotide | 113 | $64,159 |
| OzempicSemaglutide | 43 | $41,469 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 63 | $41,425 |
| ZenpepLipase/Protease/Amylase | 27 | $40,451 |
| MounjaroTirzepatide | 35 | $38,225 |
| XareltoRivaroxaban | 107 | $33,671 |
| FarxigaDapagliflozin Propanediol | 90 | $30,230 |
| TrulicityDulaglutide | 29 | $25,773 |
| Memantine Hcl | 387 | $24,491 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $384 | $247,80963 claims |
| PfizerEliquis | $15 | $151,641495 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $314 | $145,434549 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta | $17 | $84,681162 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $576 | $84,647103 claims |
| AbbVieLinzess, Creon | $15 | $79,047136 claims |
| NovartisEntresto | $94 | $66,396200 claims |
| Lilly USA, LLCMounjaro, Trulicity | $171 | $63,99864 claims |
| Aimmune Therapeutics, Inc.Zenpep | $24 | $40,45127 claims |
| Johnson & JohnsonXarelto | $55 | $33,671107 claims |
| Astellas Pharma US IncMyrbetriq | $54 | $9,97142 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $231 | $9,59613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,347 family medicine providers in Arkansas.
Other family medicine in Hot Springs
- Jodi SansonHot Springs$1.7M
- Kevin HaleHot Springs$37K
- Anna ParchmanHot Springs$28K
- Hunter CarringtonHot Springs$21K
- Scott AndersonHot Springs$15K
- Robert ParrottHot Springs$15K
- John ErwinHot Springs$12K
- George KonisLittle Rock$26.6M
- Kevin RobertsLittle Rock$2.5M
- Derek LewisLittle Rock$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.